Dore

Dore Therapeutics is an early-stage biotechnology company focused on developing novel small molecule therapies for neuropsychiatric disorders. The company leverages advanced medicinal chemistry and neurobiology to target specific G protein-coupled receptors (GPCRs) involved in mood and stress regulation. Their primary goal is to create fast-acting and more effective treatments for conditions such as treatment-resistant depression and anxiety. By focusing on precision pharmacology, Dore Therapeutics aims to minimize side effects while maximizing therapeutic efficacy in the central nervous system. The company is currently advancing its lead candidates through pre-clinical validation.